Table 3 .
65–69 years | 70–74 years | 75–79 years | 80–84 years | ≥85 years | Total | |
---|---|---|---|---|---|---|
Clinical manifestations (N/%) | ||||||
Asymptomatic | 70 (1.17) | 35 (0.97) | 19 (0.95) | 34 (2.28) | 44 (3.85) | 202 (1.42) |
Mild | 2,602 (43.56) | 1,400 (38.67) | 743 (36.98) | 488 (32.71) | 329 (28.78) | 5,562 (39.06) |
Moderate | 1,712 (28.66) | 1,031 (28.48) | 508 (25.29) | 385 (25.80) | 290 (25.37) | 3,926 (27.57) |
Severe | 1,348 (22.56) | 935 (25.83) | 591 (29.42) | 465 (31.17) | 384 (33.60) | 3,723 (26.15) |
Critical | 208 (3.48) | 193 (5.33) | 132 (6.57) | 110 (7.37) | 91 (7.96) | 734 (5.16) |
Missing | 34 (0.57) | 26 (0.72) | 16 (0.80) | 10 (0.67) | 5 (0.44) | 91 (0.64) |
Sex (N/%) | ||||||
Male | 2,889 (48.36) | 1904 (52.60) | 1,057 (52.61) | 752 (50.40) | 575 (50.31) | 7,177 (50.41) |
Female | 3,085 (51.64) | 1716 (47.40) | 952 (47.39) | 740 (49.60) | 568 (49.69) | 7,061 (49.59) |
Total population (N/%) | ||||||
Male | 268,188 (51.18) | 152,519 (50.06) | 98,040 (48.65) | 60,073 (45.35) | 34,448 (45.05) | 613,268 (49.49) |
Female | 255,812 (48.82) | 152,180 (49.94) | 103,494 (51.35) | 72,403 (54.65) | 42,014 (54.95) | 625,903 (50.51) |
Attack rate (‰) | ||||||
Male | 10.77 | 12.48 | 10.78 | 12.52 | 16.69 | 11.70 |
Female | 12.06 | 11.28 | 9.20 | 10.22 | 13.52 | 11.28 |
Total | 11.40 | 11.88 | 9.97 | 11.26 | 14.95 | 11.49 |